COVID-19 pandemic made biotech stocks very popular despite the serious economic downturn. Recent major positive 91.34% change of Navidea Biopharmaceuticals’ stock is another proof which could happen till second and third coronavirus waves. So, there is a huge space on this bandwagon for optimistic buyers who might enjoy even more dramatic changes.
Navidea Biopharmaceuticals’ internal funding does not happen since operating expenses usually exceed the gross profit by over $2 million. Only issuing shares and taking debts could help the biotech company to cover the operating costs. Soon, good news from new vaccine trials can make the total equity and stock price soar again.